Skip to main content

   Progress...

Completion of this survey is voluntary and the information collected will only be utilized by BARDA to increase the value of future BARDA Industry Days for you, our customer. For more information on privacy please visit the Privacy Notice (HTML).


1.  Organization  (required)












2.  Select the number that most closely reflects your response to each statement below.

Registration    
Was online registration easy to use?
Was the conference location appropriate for the event type?
Were area hotels and public transportation useful?
Were BARDA and AMCG staff onsite helpful?
Do you plan to attend BARDA Industry Day next year?

Day One – Innovation in products and partnerships for flexible, dynamic response capabilities

3.  Please rate 1 (Low value) to 5 (High value) based on the value of the presentation.

Presentation 1 2 3 4 5
BARDA Opening - Speaker: Dr. Rick Bright, BARDA
Keynote Day One - Speaker: Dr. Robert Kadlec, ASPR
BARDA Strategy 2017-2022 - Speaker: Dr. Rick Bright, BARDA
Chemical, Biological, Radiological, and Nuclear Threats Speaker: Dr. Joe Larson, BARDA
Pandemic Influenza and Emerging Infectious Diseases Speaker: Dr. Ruben Donis, BARDA
Reconceptualizing Diagnostics and Respiratory Protective Devices - Speaker: Dr. Julie Schafer, BARDA
Rapid Vaccine & Therapeutics Response Platforms - Speaker: Mr. Michael Angelastro, BARDA
Reflections from the FDA - Speaker: Ms. Anna Abram, FDA

Day One – Afternoon Breakout Sessions

4.  Please rate 1 (Low value) to 5 (High value) based on the value of the presentation.

Session 1 2 3 4 5
 

Chemical, Biological, Radiological and Nuclear Programs

  • Vaccines
  • Antitoxins and antivirals
  • Antibacterials
 

Design and Development Of Next Generation Pandemic Influenza Vaccines

 

Modeling: Using data to predict infectious diseases

 

Chemical, Biological, Radiological and Nuclear Programs

  • Radiological and Nuclear MCMs
  • Chemical MCMs
  • Thermal Burns
  • Biodosimetry and other CBRN Diagnostics
 

Rapid Response Manufacturing Platforms

 

Innovations in Clinical Trial Design for Emergency MCMs

 

Pandemic Influenza and Emerging Infectious Disease Programs

  • Vaccine Development
  • Vaccine Stockpile
  • Therapeutics
  • Diagnostics
 

Repurposing MCMs to Address Chemical Threat Pulmonary Injury

 

Developing Nonclinical Models with Partners


Day Two – Building Successful Partnerships and Perspectives on Contracting

5.  Please rate 1 (Low value) to 5 (High value) based on the value of the presentation.

Presentation 1 2 3 4 5
Keynote Day Two - Speaker: Senator Daschle
Partner Perspective – Speaker: Dr. Lee Swem, Achaogen, Inc.
Partner Perspective - Speaker: Dr. Paul Stoffels, Johnson & Johnson
NASA Perspective – Speaker: Dr. Craig Kundrot, NASA
Perspectives on Contracting - Speaker: Mr. Jess Scarbrough, ASPR/AMCG
BARDA Broad Agency Announcement – Speakers: Dr. Gary Disbrow, BARDA and Ms. Brooke Bernold, AMCG
Other Transaction Agreements (OTA) - Speaker: Dr. Francine Hemphill, AMCG
CARB-X - Speaker: Mr. Tyler Merkeley, BARDA
DoD Perspective - Speaker: Mr. Doug Bryce, DoD

Day Two – Afternoon Breakout Sessions

6.  Please rate 1 (Low value) to 5 (High value) based on the value of the presentation.

Session 1 2 3 4 5
 

BARDA BAA: An introduction

 

DoD/collaborating on MCM priorities

 

Emergency Use Authorizations and Pre-Authorizations for MCMs

 

The CARB –X Model

 

Other Transaction Agreements with BARDA: Concept and Experiences

 

BARDA/Success in Developing MCMs: A case study

 

Next Generation Economic Incentives for MCM Development

 

FDA/regulatory considerations for MCM development

 

CIADMs: Capabilities and How to Access Services


7.  General Comments and Suggestions: